When there are no changes to demand, increased supply reduces prices. This model of price determination can be applied to the pharmaceutical market.

For pharmaceuticals, inducing competition between pharmaceutical companies can decrease financial expenses. However, it often results in increased time for reimbursement listing. Drug prices must be adjusted through negotiation with the government, and companies cannot adjust them arbitrarily.

As we face a high-priced drug era, the government's stance is that "good things come to those who wait.' When reimbursement applications for new drugs fall into the same class, the government often discusses reimbursement listing two or even t